2月25日晚间，山西上市药企仟源医药发布公告称，公司与舟山荣豪贸易有限公司（以下简称"舟山荣豪"）联合参与浙江仟源海力生制药有限公司（以下 简称"仟源海力生"）40%股权司法拍卖，并最终以1.55亿元的价格竞得该笔股权。 仟源医药、舟山荣豪分别出资7736万元各自拿下20%股权。 根浙江省宁波市鄞州区人民法院的公告，海力生集团持有的仟源海力生40%股权于2月24日开始进行司法拍卖，标的评估价为1.77亿元，起拍价1.24亿元， 保证金2000万元。经历43次出价后，仟源医药与舟山荣豪联合体以1.55亿元的最高应价胜出。 仟源医药曾于2月24日召开的第六届董事会第二次会议审议通过相关议案，授权经营层以不超过8000万元的自有资金参与本次司法拍卖，实际出价在授权 范围内。 本次交易完成后，仟源医药持有仟源海力生80%股权，舟山荣豪持股20%。值得注意的是，二者本身就与仟源海力生渊源颇深。 值得注意的是，仟源医药原本就持有标的企业仟源海力生60%股权，此次股权交易完成后持股比例将进一步增至80%，从而进一步强化了控制权；而舟山 荣豪同样与仟源海力生渊源颇深。 仟源海力生的股权为何会走上司法程序？仟源医药、舟山荣豪看 ...

Group 1 - The core focus of the news is the establishment of the "Biopharmaceutical Innovation Alliance" in Qiantang District, aimed at addressing challenges in the biopharmaceutical industry such as long R&D cycles and complex intellectual property layouts [1][2] - Qiantang District has developed into a mature ecosystem for biopharmaceutical innovation, with over 1,800 companies in Hangzhou Medical Port, including 7 of the top 10 global pharmaceutical companies and 35 "quasi-unicorn" enterprises [2][3] - The alliance's theme is "AI + Biopharmaceuticals," aligning with national strategies in pharmaceutical technology, and aims to create a tighter collaboration network among industry, academia, and research [2][3] Group 2 - The biopharmaceutical industry in Qiantang has a revenue exceeding 50 billion yuan, supported by a 500 billion yuan industrial fund matrix to provide financial backing throughout the lifecycle of enterprises [3] - The region has established a preliminary industrial closed loop in the "AI + Biopharmaceutical" field, including AI target discovery, automated experiments, and digital clinical trials [2][3] - Qiantang District aims to achieve a biopharmaceutical industry scale exceeding 100 billion yuan by 2028, with a focus on collaboration among universities, platforms, enterprises, and the industry chain [3]

Core Viewpoint - Chengyi Pharmaceutical is committed to achieving a market value of 10 billion and becoming a century-old enterprise, focusing on three development directions: marine medicine, biomedicine, and traditional Chinese medicine [1] Group 1: Strategic Direction - The company is advancing key projects centered around the production of 2,000 tons of glucosamine raw materials and 1,000 tons of super fish oil, aiming for a strategic transformation from generic drugs to innovative drugs [1] - Chengyi Pharmaceutical is enhancing its full industry chain layout from food and health products to pharmaceuticals, driving high-quality development [1] Group 2: Product Development - The company has established a systematic marine drug development platform, integrating existing resources and expanding its product line to include high-purity EPA [1] - The infrastructure for the health industry park has been fully completed, and the ethyl ester soft capsule of EPA has received approval from the National Medical Products Administration [2] Group 3: Financial Performance - The joint drug segment has maintained an annual growth rate of over 10% since winning the national procurement bid in 2020, with revenue reaching 492 million yuan in the first three quarters of 2025, a significant increase of 42.23% year-on-year [2] - Glucosamine capsules, as a core product, continue to drive stable performance for the company [2] Group 4: Market Dynamics - The growth of joint drugs is supported by several factors, including the leading market position of glucosamine products, increased market coverage due to procurement, and enhanced brand awareness through marketing activities [2] - The demand for joint drugs is expected to continue growing due to an aging population and increasing health awareness [2][3]

Group 1 - The A-share market saw active performance in marine biopharmaceutical concept stocks, with companies like Chengyi Pharmaceutical, Haiwang Biological, and Dongfang Ocean hitting the daily limit up [1] - The Central Financial Committee emphasized the promotion of a unified national market and the high-quality development of the marine economy [1] - Chengyi Pharmaceutical, as the first listed company in Zhejiang focusing on marine biopharmaceuticals, has a revenue share of nearly 70% from this sector [1] Group 2 - Chengyi Pharmaceutical is leveraging its core businesses of glucosamine and fish oil to establish a strong presence in the marine biopharmaceutical field [1] - The company's key product, hydrochloride glucosamine, is derived from chitin sourced from crab and shrimp shells, offering unique advantages such as being all-natural and additive-free [1] - Chengyi Pharmaceutical has developed a full-chain integration advantage in glucosamine products, from raw material extraction to production [1] Group 3 - Dongfang Ocean is also gaining market attention, focusing on marine seed breeding, aquatic product processing, and biotechnology [2] - The company has established a leading position in sea cucumber farming and fish seed breeding, collaborating with institutions like the Chinese Academy of Sciences and Ocean University of China [2] - Dongfang Ocean is advancing its health industry development by establishing platforms for immune technology, mass spectrometry, molecular technology, and third-party medical testing laboratories [2]